Martin Storr

Martin Storr

Auto-generated profile, based on publicly available information

Martin Storr

Zentrum für Endoskopie, Starnberg, Germany.

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2012 in Journal of Proteome Research
Verified
Journal Article
Open access
RSRudolf Schicho
Rudolf Schicho
RSRustem Shaykhutdinov
Rustem Shaykhutdinov
JNJennifer Ngo
Jennifer Ngo
ANAlsu Nazyrova
Alsu Nazyrova
CSChristopher Schneider
Christopher Schneider
MSMartin Storr
Martin Storr
Serologic biomarkers for inflammatory bowel disease (IBD) have yielded variable differentiating ability. Quantitative analysis of a large number of metabolites is a promising method to detect IBD biomarkers. Human subjects with active Crohn’s disease (CD) and active ulcerative colitis (UC) were identified, and serum, plasma, and urine specimens were obtained. We characterized 44 serum, 37 plasma, and 71 urine metabolites by use of 1H NMR spectroscopy and “targeted analysis” to differentiate between diseased and non-diseased individuals, as well as between the CD and UC cohorts. We used multiblock principal component analysis and hierarchical OPLS-DA for comparing several blocks derived from the same “objects” (e.g., subject) to examine differences in metabolites. In serum and plasma of IBD patients, methanol, mannose, formate, 3-methyl-2-oxovalerate, and amino acids such as isoleucine were the metabolites most prominently increased, whereas in urine, maximal increases were observed for mannitol, allantoin, xylose, and carnitine. Both serum and plasma of UC and CD patients showed significant decreases in urea and citrate, whereas in urine, decreases were observed, among others, for betaine and hippurate. Quantitative metabolomic profiling of serum, plasma, and urine discriminates between healthy and IBD subjects. However, our results show that the metabolic differences between the CD and UC cohorts are less pronounced.

1 January 2011 in World Journal of Gastroenterology
Verified
Journal Article
Open access
CCChun-Qiu Chen
Chun-Qiu Chen
JFJakub Fichna
Jakub Fichna
MBMohammad Bashashati
Mohammad Bashashati
YLYong-Yu Li
Yong-Yu Li
MSMartin Storr
Martin Storr
Melatonin is a hormone with endocrine, paracrine and autocrine actions. It is involved in the regulation of multiple functions, including the control of the gastrointestinal (GI) system under physiological and pathophysiological conditions. Since the gut contains at least 400 times more melatonin than the pineal gland, a review of the functional importance of melatonin in the gut seems useful, especially in the context of recent clinical trials. Melatonin exerts its physiological effects through specific membrane receptors, named melatonin-1 receptor (MT1), MT2 and MT3. These receptors can be found in the gut and their involvement in the regulation of GI motility, inflammation and pain has been reported in numerous basic and clinical studies. Stable levels of melatonin in the lower gut that are unchanged following a pinealectomy suggest local synthesis and, furthermore, implicate physiological importance of endogenous melatonin in the GI tract. Presently, only a small number of human studies report possible beneficial and also possible harmful effects of melatonin in case reports and clinical trials. These human studies include patients with lower GI diseases, especially patients with irritable bowel syndrome, inflammatory bowel disease and colorectal cancer. In this review, we summarize the presently available information on melatonin effects in the lower gut and discuss available in vitro and in vivo data. We furthermore aim to evaluate whether melatonin may be useful in future treatment of symptoms or diseases involving the lower gut.

26 August 2016 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
CHC. Hasenoehrl
C. Hasenoehrl
UTUlrike Taschler
Ulrike Taschler
MSM. Storr
M. Storr
RSR. Schicho
R. Schicho

1 January 2012 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JFJakub Fichna
Jakub Fichna
MSMartin A. Storr
Martin A. Storr
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with an estimated prevalence of 10–20%. Current understanding of the pathophysiology of IBS is incomplete due to the lack of a clearly identified pathological abnormality and due to the lack of reliable biomarkers. Possible mechanisms believed to contribute to IBS development and IBS like symptoms include physical stressors, such as infection or inflammation, psychological, and environmental factors, like anxiety, depression, and significant negative life events. Some of these mechanisms may involve the brain-gut axis (BGA). In this article we review the current knowledge on the possible involvement of the BGA in IBS and discuss new directions for potential future therapies of IBS.

24 April 2011 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MSM. Stewart
M. Stewart
CAC. N. Andrews
C. N. Andrews
SUS. Urbanski
S. Urbanski
PBP. L. Beck
P. L. Beck
MSM. Storr
M. Storr
Background An association between microscopic colitis and coeliac disease (CD) has been suggested in literature; however, population‐based data are limited. Aims To estimate the degree of association between these two diseases and to identify possible risk factors for disease concomitance. Methods A population‐based review of all patients diagnosed with CD and microscopic colitis in a large Canadian centre over a 5‐year period. Endoscopy and pathology databases were searched to identify all cases of CD and microscopic colitis diagnosed within the Calgary Health Region between 2004 and 2008. Incidence rates were age‐standardised and gender‐standardised to 2006 Canadian Census data. standardised incidence ratios (SIR) were used to assess disease concomitance. Results Over 5 years, 763 patients were diagnosed with CD, and 1106 were diagnosed with microscopic colitis. The standardised incidence of CD ranged from 10.4 to 15.7 per 100 000 population. The standardised incidence of microscopic colitis ranged from 16.9 to 26.2 per 100 000 population. Forty patients were diagnosed with both CD and microscopic colitis, 21 of whom were middle aged (40–60 years) females. Within the CD cohort, microscopic colitis occurred at an annual rate of 11.4 per 1000 cases of CD with an overall SIR of 52.7. Conclusions There exists a strong association between microscopic colitis and CD with disease concomitance being approximately 50‐times that expected in the general population. The concomitant diagnosis of CD and microscopic colitis largely occurs in middle‐aged women. Therefore, middle‐aged women with CD and diarrhoea as a presenting or persistent symptom should undergo lower endoscopy with biopsies to rule out microscopic colitis.

10 August 2012 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
JFJ. Fichna
J. Fichna
AMA. Mokrowiecka
A. Mokrowiecka
ACA. I. Cygankiewicz
A. I. Cygankiewicz
PZPiotr Zakrzewski
Piotr Zakrzewski
Ewa Małecka-WojcieskoEwa Małecka-Wojciesko
Ewa Małecka-Wojciesko
MSM. A. Storr
M. A. Storr